Table 2. The characteristics of included studies (reports) in the systematic review and meta-analysis.
| Author | Publication year | Country | Study design | Sample type | Cervical cancer cases | Healthy controls | Cancer stage | Cut-off value | Test method | AUROC |
|---|---|---|---|---|---|---|---|---|---|---|
| Qiu et al [44] | 2020 | China | Case-control | Serum | 112 | 90 | stage I-IIA | >2 | qRT-PCR | 0.783* |
| Ma et al [69] | 2019 | China | Case-control | Plasma | 97 | 87 | stage I-II | NR | qRT-PCR | 0.677 (0.577–0.776) |
| Zamani et al [70] | 2020 | Iran | Case-control | Tissue | 50 | 46 | NR | 0.0003284 | qRT-PCR | 0.856 (0.774–0.938) |
| Jia et al [71] | 2015 | China | Case-control | Serum | 123 | 94 | Up to stage III | NR | qRT-PCR | 0.819 (0.762‑0.876) |
| Ruan et al [72] | 2020 | China | Case-control | Serum | 68 | 57 | NR | 3.855 | qRT-PCR | 0.723 (0.631–0.815) |
| Du et al [61] | 2020 | China | Case-control | Serum | 140 | 140 | stage I-II | NR | qRT-PCR | < 0.7* |
| Park et al [73] | 2017 | Korea | Case-control | Tissue | 52 | 50 | stage I-IIA | >1.975 | qRT-PCR | 0.833 (0.753–0.912) |
| Aftab et al [74] | 2021 | India | prospective | Urine | 50 | 50 | stage I-IV | 1.912 | qRT-PCR | 0.971 (0.957–0.985) |
| Aftab et al [74] | 2021 | India | prospective | Tissue | 40 | 30 | stage I-IV | 1.182 | qRT-PCR | 0.993 (0.975–1.000) |
| Zhu et al [75] | 2018 | China | Case-control | Tissue | 25 | 23 | NR | NR | qRT-PCR | 0.871 (0.743–0.950) |
NR: Not Reported
*This article was not included in the meta-analysis because only point estimate can be extracted from the article; AUROC: Area under receiver operating characteristics curve